Tag: Disease modifying therapy

In clinical trials for relapsing-remitting MS, Ocrevus was shown to reduce the number of T1 gadolinium-enhancing lesions by over 90% compared to interferon beta-1a. This powerful evidence directly addresses the question: **Does Ocrevus reduce brain lesions?** The answer, supported by extensive research, is a resounding yes, making it a pivotal treatment for multiple sclerosis.

Over 40% of people receiving Tysabri in the U.S. have been on the medication for over five years, demonstrating its long-term viability for many patients. The decision regarding *how many years can you stay on Tysabri* is not based on a set limit but on an ongoing, individualized assessment of benefit versus risk.

Multiple sclerosis predominantly affects women of childbearing age, making the question 'Is Tysabri safe for breastfeeding?' a critical one for new mothers managing their condition [1.2.4]. Recent studies offer growing reassurance for mothers facing this decision.

According to a 2019 study, nearly 1 million people in the United States are living with Multiple Sclerosis (MS) [1.7.1, 1.7.4]. For many, a cornerstone of managing the condition involves understanding the answer to: **what types of DMT are there?** These therapies are crucial for altering the disease's course.

Over 1 million Americans are living with multiple sclerosis (MS), a chronic, unpredictable disease that affects the central nervous system. In the landscape of disease-modifying therapies (DMTs), B-cell targeting agents like Kesimpta (ofatumumab) and Ocrevus (ocrelizumab) have become cornerstones of treatment for relapsing forms of MS. Choosing which is better, Kesimpta or Ocrevus, is a complex decision that involves weighing several factors, from the method of administration to subtle differences in clinical outcomes.

Mitoxantrone (Novantrone) was the first drug approved in the US for secondary progressive multiple sclerosis (SPMS), progressive-relapsing MS, and worsening relapsing-remitting MS. This potent chemotherapy drug functions as an immunosuppressant to help control the immune system's attack on the central nervous system in certain forms of MS.

An estimated 2.8 million people live with multiple sclerosis (MS) worldwide, a condition where the immune system attacks the central nervous system [1.9.1]. For many, a key question is **what is the drug Aubagio used for?** Aubagio is a prescription oral medication used to treat relapsing forms of MS in adults [1.2.1, 1.2.4].